Staurosporine

目录号:S1421 别名: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 2186.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献10篇:

客户使用该产品的4个实验数据:

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Staurosporine是一种有效的PKC抑制剂,在无细胞试验中作用于PKCα,PKCγ 和PKCη,IC50分别为2 nM,5 nM 和 4 nM,对PKCδ(20 nM)和PKCε(73 nM作用较弱,对PKCζ (1086 nM)的活性很低。同时 对其他的激酶PKA, PKG, S6K, CaMKII, 等也显示抑制活性。Phase 3。
靶点
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外研究

Staurosporine 也强抑制HeLa S3细胞,IC50为4 nM。[1]Staurosporine 也抑制多种其他蛋白激酶,包括PKA, PKG, 磷酸激酶, S6 激酶, 肌球蛋白轻链激酶(MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, 和Syk , IC50分别为 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, 和 16 nM。[3] Staurosporine (1 μM) 诱导 PC12细胞90%以上凋亡,这种作用可被过量表达的Bcl-2抑制,或者zVAD-fmk, cycloheximide (10 μM) 及actinomycin D (5 μM)处理也可抑制。相应地, Staurosporine处理,诱导细胞内游离钙水平 [Ca2+]i快速且持久的提升,线粒体活性氧(ROS)的积累,及 随后的线粒体功能障碍。[4]通过caspase-8激活和Bid 分裂,功能性caspase-3的表达可增强Staurosporine诱导MCF7细胞死亡。[5] 1 μM Staurosporine处理,只部分抑制IL-3刺激的Bcl2 磷酸化,而完全阻断PKC调节的 Bcl2磷酸化。[6] Staurosporine 诱导人类包皮成纤维细胞AG-1518凋亡,根据溶酶体组织蛋白酶D调节的 细胞色素 c释放和 caspase 激活。[7] 除了激活传统线粒体凋亡通路, Staurosporine触发一种新型内在凋亡通路, 依赖Apaf-1存在时对caspase-9的激活。[8]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MnP5R5l1d3SxeHnjxsBie3OjeR?= MVi0PEBp NH3GN2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OIUuODZizszNMi=> NWK2OWR6OjF|OEixPVE>
human colon cancer cell line (LoVo cells) NH30XYxRem:uaX\ldoF1cW:wIHHzd4F6 NIn2NZFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHPvcI9vKGOjbnPldkBk\WyuIHzpcoUhMEyxVn:gZ4VtdHNrIIXzbY5oKE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0v NXLGU|J7OTF3OUG1NFU>
human LoVo cells M3L1SHBzd2yrZnXyZZRqd25iYYPzZZk> MnjBOFghfG9iN{KgbC=> MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfS=> NIDCT4EzOjF6MkmyPS=>
P19 cells NEn0elJHfW6ldHnvckBie3OjeR?= NFnEc2tKdmirYnn0bY9vKG:oIGDsZZRmdGW2LXTldol3\WRiZ4Lve5RpKG[jY4TvdkBz\WOncITvdkBqdiCSMUmgZ4VtdHNuIFnDOVA:OC5yMEKg{txONg>? MXGxOVc4OTRzOR?=
human BJ cells NVO1eGFHS3m2b4TvfIlkyqCjc4PhfS=> NXT6UIg3PzJiaB?= NXO3Oo5CS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MD6wNFIh|ryPLh?= MWKyNlkzOTB6MR?=
human HT-29 cells M1m5bWZ2dmO2aX;uJIF{e2G7 M13jTFIhcA>? MnzDSYZn\WO2IH;uJI1qfG:laH;u[JJq[WxibXXtZpJidmVicH;0[Y51cWGuIHnuJIh2dWGwIFjUMVI6KGOnbHzzJIFnfGW{IEKgbJJ{KHW|aX7nJGpENTFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGG|c3H5 Mkj0NlE1Ojh|N{W=
human A549 cells MlrIR5l1d3SxeHnjxsBie3OjeR?= MnfkO|IhcA>? M{XzNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgcYV1cG:m M{DQXlE5PDh2N{e1
human HT-29 cells NXnNc5lUTnWwY4Tpc44h[XO|YYm= NGi2RY1KdmirYnn0bY9vKG:oIH3peI9kcG:wZILpZYwhdWWvYoLhcoUheG:2ZX70bYFtKGmwIHj1cYFvKEiWLUK5JINmdGy|IIXzbY5oKEqFMTDkfYUhe3SjaX7pcoch[nliZnz1c5Jme2OnbnPlJJBt[XSnIILlZYRmeiCjc4PhfUwhUUN3ME2yMlUhdk1? NGroPZYzOTVzM{K5Ny=>
human HT-29 cells MVfGeY5kfGmxbjDhd5NigQ>? MVuyJIg> NXvhR4dwUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBz\WS3Y4Tpc44hd2ZibXn0c4Npd26mcnnhcEBu\W2kcnHu[UBxd3SnboTpZYwh[W[2ZYKgNkBpenNiYomgeZNqdmdiSlOxJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDj[YxtNWKjc3XkJIF{e2G7LDDFR|UxRTJwNjDuUU4> M4HhWVIyQTd|MUCx
Sf9 cells Mn;5SpVv[3Srb36gZZN{[Xl? MYDJcohq[mm2aX;uJI9nKGi3bXHuJHN6cyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUOgcm0v NUTFTId1OTh6MkO3PFQ>
human HUVEC NGnESIZRem:uaX\ldoF1cW:wIHHzd4F6 M{HjVFQ5KHSxIEeyJIg> NUjjcII3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyCjZoTldkA1QCC2bzC3NkBpenNiYomgUXRVKGG|c3H5 MWWyNlE5Ojl{OR?=
P19 cells MnHkSpVv[3Srb36gZZN{[Xl? M{WzTmlvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> M1LuNVE2PzdzNEG5
Sf9 cells NIHQR2tHfW6ldHnvckBie3OjeR?= MlHxTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJI1qdiCkeTDFUGlUSSCrbjDwdoV{\W6lZTDv[kAyKHWvb3yvUEBCXFB? NUnt[VREOTd|MUW4OVM>
Sf21 cells MVXGeY5kfGmxbjDhd5NigQ>? M{S3dWlvcGmkaYTpc44hd2ZiSlHLN{BmgHC{ZYPz[YQhcW5iU3[yNUBk\WyuczygTWM2OD14IH7NMi=> M1TPclE4ODh6MEW5
human colon carcinoma cell line HCT116 Mn\mSpVv[3Srb36gZZN{[Xl? M1fPW2NwdmOnboTyZZRqd25icnXxeYlz\WRiZn;yJIdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJINwdG:wIHPhdoNqdm:vYTDj[YxtKGyrbnWgTGNVOTF4LDDJR|UxRTZibl2u NUfNcIhQOTV3M{ezOFU>
human ST486 cells MWXQdo9tcW[ncnH0bY9vKGG|c3H5 MlziOFghfG9iN{KgbC=> NGC2O25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPUOFg3KGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PyCwTT6= M2jYdFIzOTh{OUK5
human MDA-MB-231 cells MnmzR5l1d3SxeHnjxsBie3OjeR?= MVm3NkBp NYTsTZdIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2RuIFfJOVA:Py5zIH7NMi=> M{DYdVE5PDh2N{e1
P19 cells MWPGeY5kfGmxbjDhd5NigQ>? NYi3dFlOUW6qaXLpeIlwdiCxZjDDfYNtcW5vZHXw[Y5l\W62IHvpcoF{\SBzIHnuJHAyQSClZXzsd{whUUN3ME24JI5ONg>? NX7v[IRHOTV5N{G0NVk>
human DLD1 cells M1LtVXBzd2yrZnXyZZRqd25iYYPzZZk> NFjUU5o1QC15MjDo NHrmT49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTMSFEh[2WubIOgZYZ1\XJiNEigeI8hPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF06KG6PLh?= NXKwUXpvOjJzOEK5Nlk>
insect cells NXvPd4FyTnWwY4Tpc44h[XO|YYm= NHTwPYFKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? MoLpNVkyPzlyN{[=
V79 MZ cells Mn;qSpVv[3Srb36gZZN{[Xl? MVXJcohq[mm2aX;uJI9nKGi3bXHuJIFt\G:|dHXyc45mKHO7boToZZNmKGW6cILld5Nm\CCrbjDWO|khVVpiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidGSxc4Tldo9v\SC|eX70bIV{cXNuIFnDOVA:OTFibl2u NIHjNVEzPDR{MkWxPS=>
P19 cells NWDyb3NITnWwY4Tpc44h[XO|YYm= Ml\uTY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKGmwIGCxPUBk\WyuczygTWM2OD1zNDDuUU4> NHrlOpIyPTd5MUSxPS=>
Sf9 cells MXjGeY5kfGmxbjDhd5NigQ>? MYqyNEBucW6| MlTaTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCyNEBucW6|IHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUDygTWM2OD1zNTDuUU4> MmfZNVc{OTV6NUO=
human PBMC NX3zN20xTnWwY4Tpc44h[XO|YYm= NUm4fIliOjRiaB?= MWnTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? NHPUbIIyQDV6NUC0Oi=>
human A549 cells NHrtfnFEgXSxdH;4bYPDqGG|c3H5 MnvlOFghcA>? NF73cGhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVIxKG6PLh?= M4O0flI2QDJ3OUO0
human CEM cells MV;DfZRwfG:6aXRCpIF{e2G7 NHToNGw4OiCq M3PDPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1{MzDuUU4> NG\Yb3gzOjl{MUC4NS=>
human HeLa cells NXfIT3I2S3m2b4TvfIlkyqCjc4PhfS=> MVi0PEBp NHe1fIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlUhdk1w MV[yOVgzPTl|NB?=
human PC3 cells NUXIepVOS3m2b4TvfIlkyqCjc4PhfS=> NVrXTm93PDhiaB?= NFSw[GFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w NFi0XIkzPTh{NUmzOC=>
human SF268 cells NEewPYdEgXSxdH;4bYPDqGG|c3H5 M3\uRlQ5KGh? MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI3QCClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUS0JI5ONg>? MlPLNlE2OTN{OUS=
human MCF7 cells MoTHR5l1d3SxeHnjxsBie3OjeR?= MoXhOFghcA>? NW\ZUYtyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVUxKG6PLh?= Ml61NlE{QDhzOUG=
HEK293 cells MVLDfZRwfG:6aXRCpIF{e2G7 NV70SWl6PzJiaB?= NYnWbJdZS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYLHcI8h[XO|YYmsJGlEPTB;NU[gcm0v NYGzcXR[OjR5NkOyOlI>
HUE cells NH7UR4ZHfW6ldHnvckBie3OjeR?= Mk\EPVAhdWmwcx?= NGTQNZRKdmirYnn0bY9vKG:oIG\FS2ZTOiCrbjDIWWUh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQh[XW2b4Doc5NxcG:{eXzheIlwdiC2cnXheIVlKG[xcjC5NEBucW6|IHLl[o9z\SCYRVfGJINp[WyuZX7n[UBjgSCHTFnTRUwhUUN3ME23NEBvVS5? NIric5EzODF5MEG2Ny=>
human A431 cells MXTDfZRwfG:6aXRCpIF{e2G7 NFz5WlkzPCBiaB?= NFLsdHJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFI1KGi{czD1d4lv\yCDbn7lfIlvKF[nRlnUR{9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KE2WVDDhd5NigSxiSVO1NF04OCCwTT6= M3;CT|IzPTRzMEWx
human Jurkat cells NG\6UlJRem:uaX\ldoF1cW:wIHHzd4F6 NHywOmZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGpCUzNiZYjwdoV{e2mwZzDJUFIue3SrbYXsZZRm\CCqdX3hckBLfXKtYYSgZ4VtdHNuIFnDOVA:PzFibl2u M4nseFE6PDJ5MkCz
HEK293 cells MXrGeY5kfGmxbjDhd5NigQ>? M325UGlvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? MWixOVc4OTRzOR?=
human KE-97 cells MkLTR5l1d3SxeHnjxsBie3OjeR?= M{HLXlczKGh? NX3L[GhJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0VvOUegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMzFOwG0v NYjPcpp4OjR|MkiyPFM>
human CHOK1 cells M4X6T2N6fG:2b4jpZ:Kh[XO|YYm= Mof1OFghcA>? Mkm3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2hQUzFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVAvOTNizszNMi=> MkjpNlE2OTN{OUS=
mouse NIH/3T3 cells M3P0TmN6fG:2b4jpZ:Kh[XO|YYm= MUS5OkBp NXPsNoJ5S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVkmKL{PUN{Bk\WyuczDh[pRmeiB7NjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMjFOwG0v NY[zPW5NOjR|NkG1NlE>
human A2780 cells MlW5R5l1d3SxeHnjxsBie3OjeR?= NXnw[GJwQTZiaB?= NHnMeHhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u Mny4NlQ{PjF3MkG=
human 8505C cells MXLDfZRwfG:6aXRCpIF{e2G7 M4q2UFk3KGh? NX\m[XNYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hQDVyNVOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> MXSyOFM3OTV{MR?=
human 518A2 cells NXi3c2I4S3m2b4TvfIlkyqCjc4PhfS=> M4XlWFk3KGh? M3T5OGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> NWeyNVEyOjR|NkG1NlE>
human HuH7 cells MXXDfZRwfG:6aXRCpIF{e2G7 NVzPd4hJPzJiaB?= NXjHOph3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> MnfnNlQ{Ojh{OEO=
FL5.12-Akt1 cells NWTrO3dXWHKxbHnm[ZJifGmxbjDhd5NigQ>? MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\MOU4yOi2Da4SxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlI6KM7:TT6= NXLRfHBFOTZ2MEO2NlY>
human MiaPaCa-2 cells NH\YPXFRem:uaX\ldoF1cW:wIHHzd4F6 MkfCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPaXHQZWNiNTJiY3XscJMtKEmFNUC9NE4{PyEQvF2u MX2xOlQyOzd6MB?=
human BGC823 cells MVTDfZRwfG:6aXRCpIF{e2G7 M2TxelczKGh? NYO1UWZkS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1emVvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{ig{txONg>? M4PBclI1OzJ6Mkiz
human MCF7 cells NGr6VWtEgXSxdH;4bYPDqGG|c3H5 MlzzPVYhcA>? NUftNVRGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2u MkfJNlQ{PjF3MkG=
human A549 cells NVy5UnZxS3m2b4TvfIlkyqCjc4PhfS=> M3i1SFk3KGh? MlzCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOkDPxE1w NEXMblEzPDN4MUWyNS=>
HEK293 cells M4TFcGN6fG:2b4jpZ:Kh[XO|YYm= NEWwSm5EgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOsJGVEPTB;MjFOwG0v MV2yOVMyPjNzNx?=
human Raji cells  NWm5SJRES3m2b4TvfIlkyqCjc4PhfS=> NWSwNFhHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= MXyyOVMyPjNzNx?=
human HepG2 cells NVXRVph1S3m2b4TvfIlkyqCjc4PhfS=> NEXydG9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiRVO1NF0zKM7:TT6= NUH3VoNxOjV|MU[zNVc>
human BJ cells NUS0PVN[S3m2b4TvfIlkyqCjc4PhfS=> NIT6VolEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUiClZXzsd{whTUN3ME2yJO69VS5? NWO3c5hyOjV|MU[zNVc>
human U937 cells NUXN[FVIS3m2b4TvfIlkyqCjc4PhfS=> NXzaUHdSS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTl|NzDj[YxteyxiSVO1NF0zKM7:TT6= NVXrZVFNOTdyOEiwOlc>

... Click to View More Cell Line Experimental Data

体内研究 在局部贫血前,使用Staurosporine(0.1-10 ng)预处理局部贫血沙鼠和大鼠模型,可防止神经元损伤,这种作用存在剂量依赖性,说明CAl锥体细胞死亡涉及PKC。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
细胞实验:[4]
+ 展开
  • Cell lines: PC12
  • Concentrations: 溶于DMSO,终浓度为1 μM
  • Incubation Time: ~32 小时
  • Method: 使用Staurosporine处理细胞32小时。细胞在4%多聚甲醛中混合,然后使用DNA结合染料Hoechst 33342染色。在荧光照明下观察细胞,测定凋亡细胞百分数。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 短暂局部贫血的雄性Mongolian沙鼠或雄性 Wistar大鼠
  • Formulation: 溶于DMSO,然后在盐水中稀释
  • Dosages: ~10 ng
  • Administration: 定向处理到海马双边CA1子域
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 466.53
化学式

C28H26N4O3

CAS号 62996-74-1
稳定性 powder
in solvent
别名 CGP 41251

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PKC Signaling Pathway Map

相关PKC产品

Tags: 购买Staurosporine | Staurosporine供应商 | 采购Staurosporine | Staurosporine价格 | Staurosporine生产 | 订购Staurosporine | Staurosporine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID